Navigation Links
New opportunity for rapid treatment of malaria
Date:10/25/2012

Researchers have identified a new means to eradicate malaria infections by rapidly killing the blood-borne Plasmodium parasites that cause the disease.

Malaria causes up to 3 million deaths each year, predominantly afflicting vulnerable people such as children under five and pregnant women, in tropical regions of Africa, Asia, and Latin America. Treatments are available for this disease, but the Plasmodium parasite is fast becoming resistant to the most common drugs, and health authorities say they desperately need new strategies to tackle the disease.

This new potential treatment uses molecules that interfere with an important stage of the parasite's growth cycle and harnesses this effect to kill them. The impact is so acute it kills ninety per cent of the parasites in just three hours and all those tested in laboratory samples of infected human blood cells, within twelve hours.

The research was carried out by chemists at Imperial College London and biological scientists from the research institutions Institut Pasteur and CNRS in France. Their work is published in the journal Proceedings of the National Academy of Sciences (PNAS).

Lead researcher Dr Matthew Fuchter, from Imperial College London, said: "Plasmodium falciparum causes 90 per cent of malaria deaths, and its ability to resist current therapies is spreading dramatically. Whilst many new drugs are in development, a significant proportion are minor alterations, working in the same way as current ones and therefore may only be effective in the short term. We believe we may have identified the parasite's 'Achilles' Heel', using a molecule that disrupts many vital processes for its survival and development."

The research has identified two chemical compounds that affect Plasmodium falciparum's ability to carry out transcription, the key process that translates genetic code into proteins. These compounds are able to kill the parasite during the long period of its complex life cycle while it inhabits the blood-stream. This is in contrast to the majority of antimalarial drugs, whose action is limited to shorter stages of Plasmodium's life cycle.

"One particularly exciting aspect of this discovery is this new molecule's ability to rapidly kill off all traces of the parasite, acting at least as fast as the best currently available antimalarial drug," said Dr Fuchter.

Initial tests also showed the molecules were able to kill strains of Plasmodium that have developed a resistance to current treatments, although the scientists say more experiments are needed to confirm these results.

The scientists hope to refine these molecules, improving their effectiveness and proving this to be a viable strategy for treating malaria in humans. They hope it will lead to the development of an effective malaria cure within the next ten years.


'/>"/>
Contact: Simon Levey
s.levey@imperial.ac.uk
44-020-759-46702
Imperial College London
Source:Eurekalert

Related medicine news :

1. LA BioMed offers unique educational and research opportunity to local high school seniors
2. Golden Gate Opportunity: Moravia Worldwide Launches Bay Area Operation
3. Undertreatment of common heart condition persists despite rapid adoption of novel therapies
4. Obesity in Middle Age Tied to More Rapid Mental Decline: Study
5. Strawberry birthmarks grow rapidly when babies just weeks old, Mayo Clinic finds
6. UGA researchers develop rapid diagnostic test for pathogens, contaminants
7. OnPage Provides Secure, Rapid Response at New England’s Largest Catholic Hospital
8. Detecting malaria early to save lives: New optical technique promises rapid and accurate diagnosis
9. Rapid Asthma Treatment in ER May Prevent Admission
10. Satellite observes rapid ice shelf disintegration in Antarctic
11. Researchers ID potential patient population who may benefit from novel anti-platelet treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... , ... February 17, 2017 ... ... for Devicemakers , Sponsored by Axendia, **FDAnews Free Webinar**, March 1, 2017 ... manufacturers looking to reduce their regulatory burden? Pay dividends in enhanced and ...
(Date:2/18/2017)... ... February 17, 2017 , ... Park Cities Pet Sitter President, ... on the Pet Life Radio network. The episode, which was posted this week, ... including: what factors led to Park Cities Pet Sitter’s being awarded the 2017 National ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... pace. Enovate Medical has introduced an innovative workstation designed to reduce nursing fatigue ... the Encore Mobile EHR Workstation offers a lightweight, highly mobile, multi-functional alternative to ...
(Date:2/17/2017)... Falls Church, VA (PRWEB) , ... ... ... to Integrate FDA Device Approval and Reimbursement , **An FDAnews Webinar**, Feb. ... , What are the critical reimbursement questions manufacturers should be asking ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... the HIMSS17 Conference & Exhibition in Orlando, Fla., February 19-23. Visitors to the ... the most widely used electronic patient signatures solution in healthcare . ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... -- Theravance Biopharma, Inc. (NASDAQ: TBPH ... the presentation of positive clinical data for TD-1473, ... (JAK) inhibitor designed to be intestinally restricted, at ... Crohn,s and Colitis Organization (ECCO). In a poster ... completed Phase 1 study of single-ascending and multiple-ascending ...
(Date:2/17/2017)... , Feb. 17, 2017   Risperdal lawsuits involving ... allegedly associated with use of the atypical antipsychotic medication ... Court of Common Pleas, where the state,s ... program. According to a notice posted on the ... a meeting on March 9, 2017 at 11:00 a.m. ...
(Date:2/17/2017)... NEW YORK , Feb. 17, 2017 /PRNewswire/ ... announced today the partnership of their 3D body ... in healthcare IT.  The new integration will be ... on an interactive model of the human body. ... data saves clinicians time, while also increasing the ...
Breaking Medicine Technology: